Evidence map›Paper›PMID 40399657›Full record

Trial reportNeurocritical care2026

Hemoglobin and Perihematomal Edema After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial.

Alexandros A Polymeris, Vasileios-Arsenios Lioutas, Sarah Marchina, David J Seiffge, David J Roh, Fernanda Carvalho Poyraz, Magdy H Selim, i-DEF Investigators

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02175225 (Study of Deferoxamine Mesylate in Intracerebral Hemorrhage), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02175225 phase2completednot on this map

Study of Deferoxamine Mesylate in Intracerebral Hemorrhage

TypeinterventionalSponsorBeth Israel Deaconess Medical CenterRan2014 to 2018Enrolled294ConditionsIntracerebral HemorrhageArmsDeferoxamine Mesylate, Placebo (for Deferoxamine Mesylate)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandros A PolymerisStroke Division, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. alexandros.polymeris@usb.ch.ORCID 0000-0002-9475-2208
Vasileios-Arsenios LioutasStroke Division, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Sarah MarchinaStroke Division, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
David J SeiffgeDepartment of Neurology, Inselspital University Hospital Bern and University of Bern, Bern, Switzerland.
David J RohDepartment of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York City, NY, USA.
Fernanda Carvalho PoyrazDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Magdy H SelimStroke Division, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
i-DEF Investigators

Funding

Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (i-DEF)U01NS074425 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SELIM, MAGDY H · 2012 to 2016
$8.7M
NINDS NIH HHS U01 NS074425Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung P500PM_221974
6 · The paper itself

Abstract

backgroundAnemia is common after intracerebral hemorrhage (ICH). It has been attributed to inflammation and is associated with poor outcomes. We investigated whether this could be related to the effects of hemoglobin (Hb) on perihematomal edema (PHE).

methodsWe performed an exploratory post hoc analysis of the Intracerebral Hemorrhage Deferoxamine (i-DEF) randomized controlled trial. We included participants with primary supratentorial ICH, available baseline Hb levels, and computed tomography scans at baseline and follow-up after 72-96 h. We investigated the association of Hb and anemia (as continuous and dichotomous exposures, respectively) with edema extension distance (EED) as the main continuous outcome at baseline and follow-up and as its interscan change using Spearman correlation and unadjusted and adjusted linear models. We examined absolute and relative PHE in ancillary analyses.

resultsWe analyzed data from 276 of 293 (94%) i-DEF participants. The median age was 61 (interquartile range [IQR] 52-70) years, and 39% of participants were female. The median Hb level was 14.1 (IQR 13-15.2) g/dL, and 41 participants (15%) were anemic. The median EED was 4.4 (IQR 3.5-5.3) mm at baseline and 6.4 (IQR 5.3-7.3) mm at follow-up. Hb was weakly inversely correlated with baseline (ρ =  - 0.12, p = 0.05) and follow-up EED (ρ =  - 0.11, p = 0.07) but not with interscan EED change (ρ =  - 0.01, p = 0.89). Linear models showed similar relationships of Hb with baseline and particularly follow-up EED but not with EED change. In ancillary analyses, absolute and relative PHE showed no clear correlation with Hb but maintained similar relationships with Hb in linear models as in the main analysis.

conclusionsWe identified signals for an association of baseline Hb with PHE after ICH. These findings may warrant further exploration in larger cohorts. CLINICAL

trial registrationClinicalTrials.gov identifier: NCT02175225.

Indexed as

AnemiaBrain EdemaCerebral HemorrhageDeferoxamineHematomaHemoglobinsAgedFemaleHumansMaleMiddle AgedDeferoxamineHemoglobinsAnemiaEdema extension distanceHemoglobinIntracerebral hemorrhagePerihematomal edema

Identifiers

PMID40399657
PMCPMC12819462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.